Author

Claudine Wack

Observed names: C Wack, C. Wack

Institution: Sanofi (France)

Observed institution: Sanofi (France)

OpenAlex ID: A5086719409

A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma

2017 · Thomas Martin, Rachid Baz, et al. · Blood · 166

Plateable cryopreserved human hepatocytes for the assessment of cytochrome P450 inducibility: experimental condition-related variables affecting their response to inducers

2012 · Eliane Alexandre, Audrey Baze, et al. · Xenobiotica · 37

Preliminary Results from a Phase Ib Study of Isatuximab in Combination with Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma

2016 · Paul G. Richardson, Joseph Mikhael, et al. · Blood · 22

Interaction of quinolones with the theophylline metabolism in man: investigations with lomefloxacin and pipemidic acid.

1989 · A H Staib, S Harder, et al. · PubMed · 22

Preliminary Results From a Phase Ib Study of Isatuximab in Combination with Pomalidomide (Pom) and Dexamethasone (Dex) in Relapsed and Refractory Multiple Myeloma (RRMM)

2017 · Paul Richardson, Joseph Mikhael, et al. · Clinical Lymphoma Myeloma & Leukemia · 21

Phase I study of cabazitaxel plus cisplatin in patients with advanced solid tumors: study to evaluate the impact of cytochrome P450 3A inhibitors (aprepitant, ketoconazole) or inducers (rifampin) on the pharmacokinetics of cabazitaxel

2014 · John Sarantopoulos, Alain C. Mita, et al. · Cancer Chemotherapy and Pharmacology · 14

Phase I dose-escalation study of cabazitaxel administered in combination with cisplatin in patients with advanced solid tumors

2014 · A. Craig Lockhart, Shankar Sundaram, et al. · Investigational New Drugs · 12

Safety and pharmacokinetics of cabazitaxel in patients with hepatic impairment: a phase I dose-escalation study

2017 · John Sarantopoulos, Alain C. Mita, et al. · Cancer Chemotherapy and Pharmacology · 5

A phase I pharmacokinetic and safety study of cabazitaxel in adult cancer patients with normal and impaired renal function

2016 · Analía Azaro, Jordi Rodón, et al. · Cancer Chemotherapy and Pharmacology · 3

Phase I study of cabazitaxel (Cbz) plus cisplatin (Cis) in patients (pts) with advanced solid tumors: Substudy to evaluate the impact of a strong CYP3A inhibitor (ketoconazole; K) or inducer (rifampicin; R) on the pharmacokinetics (PK) of Cbz.

2013 · Alain C. Mita, Albert C. Lockhart, et al. · Journal of Clinical Oncology · 1

Absence of interaction of cabazitaxel on the pharmacokinetics of midazolam: Results of a drug–drug interaction study in patients with advanced solid tumors.

2013 · Olivier Rixe, John Sarantopoulos, et al. · Journal of Clinical Oncology · 1

Safety and pharmacokinetics (PK) of cabazitaxel (C) in patients (pts) with hepatic impairment (HI).

2015 · John Sarantopoulos, Alain C. Mita, et al. · Journal of Clinical Oncology

Pharmacokinetic (Pk) Activity of Cabazitaxel (Cbz) in Patients (Pts) with Renal Impairment (Ri)

2014 · A. Azaro, J. Rodon, et al. · Annals of Oncology

Works count: 13

Citation count: 304

H-index: 7

I10-index: 7